Cost-effectiveness of nintedanib versus pirfenidone in the treatment of idiopathic pulmonary fibrosis: a systematic review

被引：0

作者：

Rezapour, Aziz ^{[1
]}

Veysi-Sheikhrobat, Mohammad ^{[2
]}

Souresrafil, Aghdas ^{[3
]}

Moeini, Sajad ^{[2
]}

Roghani, Tayebe ^{[4
]}

Sayyad, Abdollah ^{[1
]}

Tahmasebi-Ghorrabi, Ahmad ^{[2
]}

机构：

[1] Iran Univ Med Sci, Hlth Management Res Inst, Hlth Management & Econ Res Ctr, Tehran, Iran

[2] Iran Univ Med Sci, Sch Hlth Management & Informat Sci, Dept Hlth Serv Management, Tehran, Iran

[3] Rafsanjan Univ Med Sci, Occupat Environm Res Ctr, Sch Hlth, Dept Hlth Serv & Hlth Promot, Rafsanjan, Iran

[4] Univ Tehran Med Sci, Sch Publ Hlth, Tehran, Iran

来源：

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2025年 / 25卷 / 05期

关键词：

Cost-effectiveness; economic evaluation; idiopathic pulmonary fibrosis; nintedanib; pirfenidone; systematic review; EFFICACY; SAFETY;

D O I：

10.1080/14737167.2025.2480718

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

IntroductionObjective: To systematically review studies on the cost-effectiveness of pirfenidone compared to nintedanib in patients with idiopathic pulmonary fibrosis (IPF).MethodsData sources: PubMed, EMBASE, Scopus, and Web of Science. Inclusion criteria: Full economic evaluations comparing pirfenidone versus nintedanib inIPF patients. Assessment: Quality of Health Economic Studies (QHES) tool forstudy quality.ResultsNine studies met the inclusion criteria with QHES scores of 0.91 or higher. The incremental cost-effectiveness ratios (ICERs) ranged from $66,434 to $1,668,321 per quality-adjusted life year (QALY) in the United States. Nintedanib was found to be cost-effective in five studies.ConclusionsNintedanib appears to be a more cost-effective treatment for IPF compared to pirfenidone. Further research is needed, particularly in low- and middle-income countries, considering healthcare system perspectives and varied willingness-to-pay thresholds.RegistrationPROSPERO (CRD42024543954)

引用

页码：661 / 669

页数：9

共 25 条

[1]

[2]

CADTH Common Drug Reviews, PHARMACOECONOMIC REP

[3] Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows [J].

Chianese, Maria ;

Screm, Gianluca ;

Salton, Francesco ;

Confalonieri, Paola ;

Trotta, Liliana ;

Barbieri, Mariangela ;

Ruggero, Luca ;

Mari, Marco ;

Reccardini, Nicolo ;

Geri, Pietro ;

Hughes, Michael ;

Lerda, Selene ;

Confalonieri, Marco ;

Mondini, Lucrezia ;

Ruaro, Barbara .

PHARMACEUTICALS, 2024, 17 (06)

[4]

Clay Emilie, 2019, J Mark Access Health Policy, V7, P1626171, DOI 10.1080/20016689.2019.1626171

[5]

Collard Harold R, 2012, J Med Econ, V15, P829, DOI 10.3111/13696998.2012.680553

[6] Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis [J].

Cottin, Vincent ;

Spagnolo, Paolo ;

Bonniaud, Philippe ;

Dalond, Faustine ;

Nolind, Maeva ;

Kirchgassler, Klaus-Uwe ;

Van Ganse, Eric ;

Belhassen, Manon .

RESPIRATORY MEDICINE AND RESEARCH, 2023, 83

[7] Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States [J].

Dempsey, Timothy M. ;

Thao, Viengneesee ;

Moriarty, James P. ;

Borah, Bijan J. ;

Limper, Andrew H. .

BMC PULMONARY MEDICINE, 2022, 22 (01)

[8] Idiopathic pulmonary fibrosis: present understanding and future options [J].

du Bois, R. M. .

EUROPEAN RESPIRATORY REVIEW, 2011, 20 (121) :132-133

[9] Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry [J].

Fan, Yanni ;

Bender, Shaun D. ;

Conoscenti, Craig S. ;

Davidson-Ray, Linda ;

Cowper, Patricia A. ;

Palmer, Scott M. ;

de Andrade, Joao A. .

CHEST, 2020, 157 (06) :1522-1530

[10] Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis [J].

Finnerty, James Patrick ;

Ponnuswamy, Aravind ;

Dutta, Prosjenjit ;

Abdelaziz, Ammar ;

Kamil, Hafiz .

BMC PULMONARY MEDICINE, 2021, 21 (01)

← 1 2 3 →